72 results on '"Hou JZ"'
Search Results
2. Leukemia cutis and anterior uveitis associated with chronic myelomonocytic leukemia.
- Author
-
Harper KK, Mutch V, Safran JP, Wu D, Aggarwal N, Maheshwari E, Weinstock AK, Gibson KF, Errera MH, Hou JZ, Karunamurthy AD, and Bunimovich YL
- Abstract
Competing Interests: None disclosed
- Published
- 2024
- Full Text
- View/download PDF
3. Developing critical HIV health literacy: insights from interviews with priority migrant communities in Queensland, Australia.
- Author
-
Istiko SN, Remata S, Ndayizeye A, Moreno MEV, Kirunda V, Hollingdrake O, Osborne R, Hou JZ, Abell B, Mullens AB, Gu Z, Debattista J, Vujcich D, Lobo R, Parma G, Howard C, and Durham J
- Subjects
- Humans, Queensland, Male, Adult, Female, Interviews as Topic, Middle Aged, Sexual and Gender Minorities, Africa South of the Sahara ethnology, Health Literacy, HIV Infections prevention & control, Transients and Migrants psychology, Qualitative Research
- Abstract
In Australia, surveillance data establish that there are higher rates of late HIV diagnoses among heterosexual migrants from Sub-Saharan Africa and new HIV diagnoses among gay and bisexual men (GBM) from Southeast and Northeast Asia and Latin America. Together, these groups are identified as priority migrant communities in current efforts to eliminate HIV transmissions. HIV health literacy is recognised as a key means of improving access to services and health outcomes. This qualitative paper explores critical HIV health literacy among priority migrant communities in Queensland, Australia. To foreground community voices, peer researchers from priority migrant communities participated in the project design, data collection and analysis, with 20 interviews completed. The findings demonstrate how participants' engagement with HIV health information and services is highly relational and situated within the framework of sexual health and wellbeing. Participants strategically selected where to seek information and who they trusted to help them appraise this information. They further demonstrated reflective capacities in identifying the contextual barriers that inhibit the development of their HIV health literacy. The findings highlight the need for HIV health promotion strategies that embrace a sex positive approach, promote cultural change, and involve collaboration with general practitioners (GPs).
- Published
- 2024
- Full Text
- View/download PDF
4. [Analysis of a family with 11β-hydroxylase deficiency due to a mutation in the CYP11B1 gene].
- Author
-
Yu YY, Tao YK, Hou JZ, Zhou GX, Du JJ, and Zhang D
- Subjects
- Humans, Male, Female, Retrospective Studies, Exons, Heterozygote, Pedigree, Steroid 11-beta-Hydroxylase genetics, Adrenal Hyperplasia, Congenital genetics, Mutation
- Abstract
This study reports a family of patients with 11β-hydroxylase deficiency (11β-OHD) caused by a novel mutation in the CYP11B1 gene, and analyzes its clinical and genetic characteristics. The clinical data of a patient with intractable hypertension at Air Force Medical Center on May 16, 2014 were retrospectively analyzed. The patient was clinically diagnosed with congenital adrenal cortical hyperplasia. The clinical data of the patient were further collected and the peripheral blood samples of the patient, his parents and his sister were collected for CYP11B1(NM_000497) gene sequencing, suggesting that the patient had compound heterozygous mutations in exon 1:c.199delG, p.Glu67Lysfs*9 and exon 5:c.905_907 delATGinsTT, p.Asp302Valfs*23, both of which were pathogenic variants. The patient's father and sister carried heterozygous mutations in exon 1:c.199delG, p.Glu67Lysfs*9, and the mother carried heterozygous mutations in exon 5:c.905_907delATGinsTT, p.Asp302Valfs*23. This study is the first to report a new compound heterozygous mutation in exon 1:c.199delG and exon 5 c.905_907 delATGinsTT of CYP11B1 gene, enriching the database of 11β-OHD mutations and providing information to further understand the genetic mechanism of the disease.
- Published
- 2024
- Full Text
- View/download PDF
5. Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
- Author
-
Im A, Quann K, Agha M, Raptis A, Redner RL, Hou JZ, Farah R, Dorritie KA, Sehgal AR, Normolle D, Bovbjerg DH, Aggarwal N, Herman J, Lontos K, and Boyiadzis M
- Subjects
- Aged, Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Decitabine, Epigenesis, Genetic, Remission Induction, Treatment Outcome, Cytarabine, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics
- Abstract
Acute myeloid leukemia (AML) in older patients has a poor prognosis, low complete remission (CR) rates, and poor overall survival (OS). Preclinical studies have shown synergistic effects of epigenetic priming with hypomethylating agents followed by cytarabine. Based on these data, we hypothesized that an induction regimen using epigenetic priming with decitabine, followed by cytarabine would be effective and safe in older patients with previously untreated AML. Here, we conducted a phase 2 trial in which older patients with previously untreated AML received an induction regimen consisting of 1 or 2 courses of decitabine 20 mg/m
2 intravenously (IV) for 5 days followed by cytarabine 100 mg/m2 continuous IV infusion for 5 days. Forty-four patients (median age 76 years) were enrolled, and CR/CRi was achieved by 26 patients (59% of all patients, 66.7% of evaluable patients). Fourteen of 21 (66.7%) patients with adverse cytogenetics achieved CR including six out of seven evaluable patients with TP53 mutations. The 4- and 8-week mortality rates were 2.3% and 9.1%, respectively, with median OS of 10.7 months. These results suggest epigenetic priming with decitabine followed by cytarabine should be considered as an option for first-line therapy in older patients with AML. This trial was registered at www.clinicaltrials.gov as # NCT01829503., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
6. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
- Author
-
Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, García-Sancho AM, Glazunova V, Grigg A, Hou JZ, Janssens A, Kim SJ, Masliak Z, McKay P, Merli F, Munakata W, Nagai H, Özcan M, Preis M, Wang T, Rowe M, Tamegnon M, Qin R, Henninger T, Curtis M, Caces DB, Thieblemont C, and Salles G
- Subjects
- Adult, Humans, Rituximab adverse effects, Bendamustine Hydrochloride therapeutic use, Piperidines therapeutic use, Vincristine adverse effects, Cyclophosphamide adverse effects, Prednisone adverse effects, Doxorubicin adverse effects, Lymphoma, B-Cell, Marginal Zone drug therapy, Lymphoma, Follicular drug therapy
- Abstract
The phase 3 SELENE study evaluated ibrutinib + chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL). Adult patients who had received ≥1 prior line of CIT were randomized 1:1 to oral ibrutinib (560 mg) or placebo daily, plus 6 cycles of BR/R-CHOP. The primary end point was investigator-assessed progression-free survival (PFS). Overall, 403 patients were randomized to ibrutinib + CIT (n = 202) or placebo + CIT (n = 201). Most patients received BR (90.3%) and had FL (86.1%). With a median follow-up of 84 months, median PFS was 40.5 months in the ibrutinib + CIT arm and 23.8 months in the placebo + CIT arm (hazard ratio [HR], 0.806; 95% confidence interval [CI], 0.626-1.037; P = .0922). Median overall survival was not reached in either arm (HR, 0.980; 95% CI, 0.686-1.400). Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 85.6% and 75.4% of patients in the ibrutinib + CIT and placebo + CIT arms, respectively. In each arm, 13 patients had TEAEs leading to death. The addition of ibrutinib to CIT did not significantly improve PFS compared with placebo + CIT. The safety profile was consistent with known profiles of ibrutinib and CIT. This trial was registered at www.clinicaltrials.gov as #NCT01974440., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Association between micronutrients intake and metabolic-associated fatty liver disease: a cross-sectional study based on the National Health and Nutrition Examination Survey.
- Author
-
Hou JZ, Wu QW, and Zhang L
- Subjects
- Humans, Nutrition Surveys, Cross-Sectional Studies, Copper, Eating, Iron, Micronutrients, Non-alcoholic Fatty Liver Disease
- Abstract
Metabolic-associated fatty liver disease (MAFLD) has been proposed to replace the term non-alcoholic fatty liver disease (NAFLD) in 2020. The association between micronutrients and MAFLD has not been reported. Therefore, this study aims to explore the association between micronutrients intake and MAFLD. This was a cross-section study based on the National Health and Nutrition Examination Survey (NHANES). The dietary intake of copper, zinc, iron, and selenium was evaluated using the 24-h dietary recall interview. Logistic regression analysis was used to explore the association between micronutrients and MAFLD, and the results were shown as odds ratio (OR) with 95 % confidence intervals (CIs). A total of 5976 participants were finally included for analysis, with 3437 participants in the MAFLD group. After adjusting potential confounders, copper intake at quartile Q3 (OR = 0⋅68, 95 % CI 0⋅50, 0⋅93) and Q4 (OR = 0⋅60, 95 % CI 0⋅45, 0⋅80) was found to be associated with lower odds of MAFLD. Iron intake at Q2 (OR = 0⋅64, 95 % CI 0⋅45, 0⋅92) and Q3 (OR = 0⋅61, 95 % CI 0⋅41, 0⋅91) was associated with the lower odds of MAFLD. Our findings found that high intake of copper and adequate intake of iron were associated with MAFLD, which may provide guidance for the management of MAFLD., (© The Author(s) 2023.)
- Published
- 2023
- Full Text
- View/download PDF
8. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
- Author
-
Jonas BA, Hou JZ, Roboz GJ, Alvares CL, Jeyakumar D, Edwards JR, Erba HP, Kelly RJ, Röllig C, Fiedler W, Brackman D, Siddani SR, Chyla B, Hilger-Rolfe J, and Watts JM
- Subjects
- Humans, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute etiology
- Abstract
Relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) is a genetically complex and heterogeneous disease with a poor prognosis and limited treatment options. Thus, there is an urgent need to develop therapeutic combinations to overcome drug resistance in AML. This open-label, multicenter, international, phase 1b study evaluated the safety, efficacy, and pharmacokinetics of venetoclax in combination with alvocidib in patients with R/R AML. Patients were treated with escalating doses of venetoclax (400, 600, and 800 mg QD, orally, days 1-28) and alvocidib (45 and 60 mg/m
2 , intravenously, days 1-3) in 28-day cycles. The combination was found to be safe and tolerable, with no maximum tolerated dose reached. Drug-related Grade ≥3 adverse events were reported in 23 (65.7%) for venetoclax and 24 (68.6%) for alvocidib. No drug-related AEs were fatal. Gastrointestinal toxicities, including diarrhea, nausea, and vomiting were notable and frequent; otherwise, the toxicities reported were consistent with the safety profile of both agents. The response rate was modest (complete remission [CR] + incomplete CR [CRi], 11.4%; CR + CRi + partial response rate + morphologic leukemia-free state, 20%). There was no change in alvocidib pharmacokinetics with increasing doses of venetoclax. However, when venetoclax was administered with alvocidib, AUC24 and Cmax decreased by 18% and 19%, respectively. A recommended phase 2 dose was not established due to lack of meaningful increase in efficacy across all cohorts compared to what was previously observed with each agent alone. Future studies could consider the role of the sequence, dosing, and the use of a more selective MCL1 inhibitor for the R/R AML population., (© 2023 AbbVie Inc. Hematological Oncology published by John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
9. Hexacyclic Chelated Lithium Stable Solvates for Highly Reversible Cycling of High-Voltage Lithium Metal Battery.
- Author
-
Wu LQ, Li Z, Lu Y, Hou JZ, Han HQ, Zhao Q, and Chen J
- Abstract
Ether-based electrolytes that are endowed with decent compatibility towards lithium anode have been regarded as promising candidates for constructing energy-dense lithium metal batteries (LMBs), but their applications are hindered by low oxidation stability in conventional salt concentration. Here, we reported that regulating the chelating power and coordination structure can remarkably increase the high-voltage stability of ether-based electrolytes and lifespan of LMBs. Two ether molecules of 1,3-dimethoxypropane (DMP) and 1,3-diethoxypropane (DEP) are designed and synthesized as solvents of electrolytes to replace the traditional ether solvent (1,2-dimethoxyethane, DME). Both computational and spectra reveal that the transition from five- to six-membered chelate solvation structure by adding one methylene on DME results in the formation of weak Li solvates, which increase the reversibility and high-voltage stability in LMBs. Even under lean electrolyte (5 mL Ah
-1 ) and low anode to cathode ratio (2.6), the fabricated high-voltage Li||LiNi0.8 Co0.1 Mn0.1 O2 LMBs using electrolyte of 2.30 M Lithiumbisfluorosulfonimide (LiFSI)/DMP still show capacity retention over 90 % after 184 cycles. This work highlights the importance of designing the coordination structures in non-fluorine ether electrolytes for rechargeable batteries., (© 2023 Wiley-VCH GmbH.)- Published
- 2023
- Full Text
- View/download PDF
10. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
- Author
-
Barrientos JC, Ayed AO, Cha A, Du S, Fang B, Hall R, Marks SM, Peng E, Rhodes JM, Ryan K, Winters SB, Yeung PL, and Hou JZ
- Subjects
- Adult, Humans, Race Factors, Retrospective Studies, Disease Progression, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
Background: Despite recent approvals of lifesaving treatments for chronic lymphocytic leukemia (CLL), real-world data on the tolerability of the Bruton tyrosine kinase inhibitor ibrutinib for CLL treatment are lacking, especially in Black patients., Objective: To expand upon a previously reported retrospective chart review of ibrutinib-treated patients with CLL to increase the number of sites and the enrollment period in first-line (1L) and relapsed/refractory (R/R) settings with a subanalysis based on ethnicity., Patients and Methods: Adults with CLL who initiated ibrutinib treatment from five centers were followed for ≥ 6 months., Results: We identified 482 patients with CLL [405 White (153 1L, 252 R/R), 37 Black (17 1L, 20 R/R), 40 other/unidentified]. At baseline, 58.5% of all patients (68.8% of Black patients) had hypertension. At a median follow-up of 28.2 months, 31.1% of patients overall discontinued ibrutinib, 16.2% due to adverse events (12.2% 1L, 18.8% R/R). Overall, 46.0% of patients experienced ≥ 1 dose hold (40.2% 1L, 49.8% R/R), and 28.8% of patients experienced ≥ 1 dose reduction (24.9% 1L, 31.4% R/R). Among Black patients, ibrutinib was discontinued in 24.3% of patients (17.6% 1L, 30.0% R/R), 8.1% due to disease progression and 5.4% due to adverse events; 40.5% of patients experienced ≥ 1 dose hold (35.3% 1L, 45.0% R/R), and 32.4% of patients experienced ≥ 1 dose reduction (23.5% 1L, 40.0% R/R)., Conclusions: Toxicity and disease progression were the most common reasons for ibrutinib discontinuations in the overall population and among Black patients, respectively. Encouraging research participation of underrepresented patient groups will help clinicians better understand treatment outcomes., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
11. Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report.
- Author
-
Hou JZ, Dong NN, Yue B, Meng FD, and Wang YJ
- Subjects
- Male, Humans, Middle Aged, Gastric Mucosa pathology, Stomach Neoplasms pathology, Polyps pathology, Adenomatous Polyps complications, Adenomatous Polyps pathology, Gastritis complications, Gastritis diagnosis, Gastritis surgery, Hamartoma diagnosis, Hamartoma pathology, Hamartoma surgery
- Abstract
We report an unusual case of autoimmune gastritis (AIG) complicated with a submucosal tumor (SMT) and two pedunculated polyps in a 60-year-old man. The patient was admitted for epigastric distention, heartburn, and anorexia. Endoscopy showed an SMT in the fundus, two pedunculated polyps in the body, and markedly atrophic mucosa of the body and fundus. The SMT, measuring 20 mm in diameter, was resected by endoscopic submucosal dissection and histologically diagnosed as a gastric hamartomatous inverted polyp (GHIP), which is characterized by submucosal glandular proliferation, cystic dilatation, and calcification. The gland structures consisted of foveolar cells and pseudopyloric or mucous-neck cell types. The two pedunculated polyps that were resected by endoscopic mucosal resection were histologically diagnosed as hyperplastic polyps, which are characterized by hyperplastic foveolar glands with pseudopyloric or mucous-neck glands in the inflamed stroma in the mucosa, which consisted of almost the same types of lining cells as the GHIP in the fundus. Findings may indicate the relationship between GHIP, hyperplastic polyp, and AIG. We highlight considering GHIP as a differential diagnosis for an SMT in patients with AIG.
- Published
- 2023
- Full Text
- View/download PDF
12. Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.
- Author
-
Lontos K, Tsagianni A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Aggarwal N, Saul M, Boyiadzis M, and Bailey NG
- Subjects
- Humans, Prognosis, Remission Induction, Biopsy, Bone Marrow pathology, Bone Marrow Cells pathology
- Published
- 2023
- Full Text
- View/download PDF
13. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
- Author
-
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, and DiNardo CD
- Subjects
- Humans, Follow-Up Studies, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute etiology
- Published
- 2022
- Full Text
- View/download PDF
14. A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.
- Author
-
Lontos K, Tsagianni A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Aggarwal N, Saul M, Gooding W, and Boyiadzis M
- Subjects
- Humans, Nomograms, Cytogenetics, Nuclear Proteins genetics, Cytogenetic Analysis, Mutation, Prognosis, fms-Like Tyrosine Kinase 3, Tumor Suppressor Protein p53 genetics, Induction Chemotherapy, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics
- Published
- 2022
- Full Text
- View/download PDF
15. The Direct Anterior Approach versus the Posterolateral Approach on the Outcome of Total Hip Arthroplasty: A Retrospective Clinical Study.
- Author
-
Wang Z, Bao HW, Hou JZ, Ju B, Wu CH, Zhou YJ, Gu XM, and Wang HH
- Subjects
- Blood Loss, Surgical, Humans, Retrospective Studies, Treatment Outcome, Arthroplasty, Replacement, Hip methods
- Abstract
Objective: To compare the clinical results of the direct anterior approach (DAA) and posterolateral approach (PLA) in total hip arthroplasty (THA) patients., Methods: From January 2017 to September 2019, 80 patients who received primary THA in our hospital were retrospectively selected based on the propensity score matching (PSM) method. Baseline characteristics of patients who underwent the DAA and PLA were collected. Moreover, the incision length, intraoperative blood loss, operative time, length of stay, and Harris hip score were compared between patients in the two groups. The CK level was used to assess muscle damage between patients in the DAA and PLA groups. The complications of these two approaches were also evaluated at patients' 12-month follow-up evaluation., Results: There was no significant difference in baseline characteristics between patients in the two groups (p > 0.05). The patients in the DAA group had a shorter incision length (9.2 ± 0.2 vs 14.7 ± 0.5, respectively; p < 0.05) and shorter length of hospital stay (9.5 ± 0.7 vs 12.9 ± 0.8, respectively, p < 0.05) than patients in the PLA group. Moreover, the DAA was associated with a decrease in intraoperative blood loss compared with the PLA (109.1 ± 12.6 vs 305.1 ± 14.1 ml, respectively, p < 0.05). However, the operation time was longer in patients in the DAA group (130.7 ± 1.7) than in patients in the PLA group (112.6 ± 1.3 min, p < 0.05). The CK level of patients in the DAA group was lower than that of patients in the PLA group (p < 0.05). The CK level at 48 h post-surgery was negatively correlated with the Harris hip scores at 6 months after THA (r = -0.538, p = 0.000). Compared with patients in the PLA group, the muscle strength of patients in the DAA group was significantly higher than that of patients in the DAA group at 4 days (p < 0.05) and 7 days (p < 0.05) after THA. The Harris hip scores of patients in the DAA group and PLA group were 81.0 ± 0.8 vs 70.8 ± 0.7 at 6 weeks, 93.4 ± 0.9 vs 86.4 ± 0.6 at 3 months, and 96.8 ± 1.1 vs 93.4 ± 0.8 at 6 months, respectively, both p < 0.05. There was no significant difference in the incidence of complications between patients in the DAA and PLA groups (p > 0.05)., Conclusion: DAA was superior to the PLA in improving hip function after THA. Compared with the PLA, the DAA could reduce muscle damage, which is negatively correlated with hip function. Further multi-institution studies are required with longer follow-up durations, and larger patient populations are needed to provide more definitive conclusions., (© 2022 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
16. Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers.
- Author
-
Posluszny DM, Bovbjerg DH, Syrjala KL, Agha M, Farah R, Hou JZ, Raptis A, Im AP, Dorritie KA, Boyiadzis MM, and Dew MA
- Subjects
- Humans, Quality of Life psychology, Caregivers psychology, Hematopoietic Stem Cell Transplantation psychology
- Abstract
Allogeneic hematopoietic cell transplantation (HCT) requires a complex, multicomponent medical regimen after hospital discharge. Patients must manage multiple medications; care for their catheter; minimize exposure to sources of potential infection; follow diet, exercise, and self-care guidelines; and attend frequent follow-up medical appointments. Their caregivers are tasked with helping them manage the regimen. Despite the importance of this management in preventing adverse clinical outcomes, there has been little study of regimen nonadherence and its predictors. We sought to prospectively determine rates and predictors of nonadherence to components of the post-HCT medical regimen during the first 8 weeks after hospital discharge. Patients (n = 92) and their caregivers (n = 91) (total n = 183) completed interview assessments pre-HCT, and at 4 weeks and 8 weeks after hospital discharge post-HCT. Sociodemographic factors (eg, age, sex), patient clinical status (eg, disease type, donor type), patient and caregiver self-reported health-related factors (eg, medical comorbidities), and patient and caregiver psychosocial factors (eg, anxiety, depression, HCT task-specific and general self-efficacy, relationship quality) were assessed pre-HCT. Nonadherence to each of 17 regimen tasks was assessed at 4 and 8 weeks after hospital discharge via self and caregiver collateral reports. Nonadherence rates varied among tasks, with 11.2% to 15.7% of the sample reporting nonadherence to immunosuppressant medication, 34.8% to 38.6% to other types of medications, 14.6% to 67.4% to required infection precautions, and 27.0% to 68.5% to lifestyle-related behaviors (eg, diet/exercise). Nonadherence rates were generally stable but worsened over time for lifestyle-related behaviors. The most consistent nonadherence predictors were patient and caregiver pre-HCT perceptions of lower HCT task efficacy. Higher caregiver depression, caregiver perceptions of poorer relationship with the patient, having a nonspousal caregiver, and having diseases other than acute myelogenous leukemia also predicted greater nonadherence in 1 or more areas. Rates of nonadherence varied across tasks, and both patient and caregiver factors, particularly self-efficacy, predicted nonadherence. The findings highlight the importance of considering not only patient factors, but also caregiver factors, in post-HCT regimen nonadherence., (Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
17. A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy.
- Author
-
McKeown C, Ricciuti A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Lontos K, Bovbjerg DH, Normolle D, and Boyiadzis M
- Subjects
- Adult, Humans, Induction Chemotherapy, Middle Aged, Prospective Studies, Quality of Life, Risk Factors, Catheter-Related Infections epidemiology, Catheterization, Central Venous adverse effects, Catheterization, Peripheral adverse effects, Central Venous Catheters adverse effects, Leukemia, Myeloid, Acute drug therapy
- Abstract
Purpose: Central venous catheters (CVCs) are widely used in acute myeloid leukemia (AML) patients. Complications associated with CVCs are frequently encountered and contribute to morbidity and mortality. Prospective studies investigating and comparing complications of different types of CVCs in AML patients and their effects on the quality of life are limited., Methods: We conducted a prospective observational study and evaluated the complications associated with the use of CVCs in adult AML patients during induction chemotherapy and evaluated quality of life outcomes as reported by the patients during and after their hospitalization., Results: Fifty newly diagnosed patients with AML (median age, 59 years) who received intensive induction chemotherapy were enrolled in the study. Twenty-nine patients (58%) had a peripherally inserted central catheters (PICCs) placed and 21 (42%) patients received a Hickmann tunneled central catheter (TCC). Three percent of cases developed catheter-related thrombosis in PICCs and no thrombosis in TCCs. Catheter-related bloodstream infection was diagnosed in 8% of patients. CVC occlusion occurred in 44 patients (88%). The total number of occlusion events was 128; 97% of patients with PICCs and 76% of patients with TCCs (p = 0.003). All patients reported that the use of CVC simplified their course of treatment. Most patients reported similar restrictions in activity associated with TCCs and PICCs., Conclusion: The present study demonstrates that thrombosis and catheter-related bloodstream infections remain important complications of CVCs in AML patients. Occlusion rates were higher with the use of PICCs and the use of CVCs impacted the quality of life., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
18. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
- Author
-
Hou JZ, Ryan K, Du S, Fang B, Marks S, Page R, Peng E, Szymanski K, Winters S, and Le H
- Subjects
- Adenine administration & dosage, Adenine adverse effects, Adult, Aged, Aged, 80 and over, Clinical Decision-Making, Disease Management, Drug Resistance, Neoplasm, Drug Tapering, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell etiology, Male, Middle Aged, Molecular Targeted Therapy methods, Piperidines adverse effects, Protein Kinase Inhibitors adverse effects, Recurrence, Retrospective Studies, Withholding Treatment, Adenine analogs & derivatives, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Piperidines administration & dosage, Protein Kinase Inhibitors administration & dosage
- Abstract
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
19. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
- Author
-
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, and DiNardo CD
- Published
- 2021
- Full Text
- View/download PDF
20. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
- Author
-
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, and DiNardo CD
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality
- Abstract
VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine (+LDAC) in patients with untreated AML ineligible for intensive chemotherapy. Overall, 211 patients were enrolled (n = 143, venetoclax; n = 68, placebo). At the primary analysis, the study did not meet its primary endpoint of a statistically significant improvement in overall survival (OS), however, ~60% of patients had been on study for ≤6-months. Here, we present an additional 6-months of follow-up of VIALE-C (median follow-up 17.5 months; range 0.1-23.5). Median OS was (venetoclax +LDAC vs. placebo +LDAC) 8.4 vs. 4.1 months (HR = 0.70, 95% CI 0.50,0.99; P = 0.040); a 30% reduction in the risk of death with venetoclax. Complete response (CR)/CR with incomplete hematologic recovery (CRi) rates were 48.3% vs. 13.2%. Transfusion independence rates (RBC) were 43% vs.19% and median event-free survival was 4.9 vs. 2.1 months (HR = 0.61; 95% CI 0.44,0.84; P = 0.002). These results represent improved efficacy over the primary analysis. Incidence of grade ≥3 adverse events were similar between study arms and overall safety profiles were comparable to the primary analysis. These data support venetoclax +LDAC as a frontline treatment option for patients with AML ineligible for intensive chemotherapy.This trial was registered at www.clinicaltrials.gov as #NCT03069352., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
21. Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission.
- Author
-
Patel A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Normolle D, Lontos K, and Boyiadzis M
- Subjects
- Adolescent, Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Cohort Studies, Decitabine therapeutic use, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Prognosis, Recurrence, Remission Induction, Retrospective Studies, Survival Rate, Time Factors, Transplantation, Homologous methods, Treatment Outcome, Young Adult, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Neoplasm Recurrence, Local pathology
- Abstract
Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.116.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with an overall CR rate of 66%. The median time to relapse after achieving second CR (CR2) was 16.5 months [95% confidence interval (CI): 9.4, NA]. The median overall survival after first relapse was 28.6 months (95% CI: 7.3, 3.466.5 months). Despite initial CR after reinduction therapy, relapse rates are still high, suggesting that alternative strategies for postremission therapies are warranted in CR2. These approaches include the use of allogeneic hematogenic cell transplantation and the use of newly approved AML agents as maintenance therapy in nontransplant eligible patients.
- Published
- 2021
- Full Text
- View/download PDF
22. Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials.
- Author
-
Wu QQ, Gao H, Du SS, Chen YX, Hu Y, Yang P, Hou JZ, and Zeng ZC
- Subjects
- China, Humans, Network Meta-Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Carcinoma, Hepatocellular secondary, Carcinoma, Hepatocellular therapy, Hepatic Veins, Liver Neoplasms pathology, Liver Neoplasms therapy, Neoplastic Cells, Circulating, Portal Vein
- Abstract
Purpose: To assess the efficacy and safety of different peri-operative regimens using the network meta-analysis for hepatocellular carcinoma (HCC) with portal/hepatic vein tumor thrombosis. The interested modalities included neoadjuvant three-dimensional radiotherapy (3D-CRT), post-operative intensity modulated radiation therapy (IMRT), post-operative transarterial chemoembolization (TACE), 3DCRT plus TACE and surgery alone., Methods: PubMed and Cochrane Library electronic databases were systematically searched for eligible studies published up to March 2021. Data related to treatment efficacy including overall survival (OS) and disease-free survival (DFS) were extracted and compared using a Bayesian approach. Adverse events (AEs) were assessed and compared., Results: Five studies published between 2009 and 2021 were enrolled in this network meta-analysis. The comparison showed that surgery with IMRT ranks relatively higher in prolonging OS in advanced HCC patients, followed by neoadjuvant 3DCRT and surgery plus TACE. Neoadjuvant 3DCRT and postoperative IMRT appear to be better choices than 3DCRT plus TACE in terms of OS. IMRT, TACE and neoadjuvant 3DCRT group were all superior to surgery alone in terms of DFS. The rate of AEs did not differ significantly., Conclusions: Adjuvant IMRT showed more favorable treatment responses compared to other regimens in HCC patients as a peri-operative regimen.
- Published
- 2021
23. [Application value of liquid crystal digital display goniometer in total hip arthroplasty].
- Author
-
Hou JZ, Wang HH, Cheng YX, Bao HW, Wang YJ, and Sun Y
- Subjects
- Acetabulum surgery, Female, Humans, Male, Retrospective Studies, Arthroplasty, Replacement, Hip, Hip Prosthesis, Liquid Crystals
- Abstract
Objective: To investigate the application value of liquid crystal digital display goniometer in total hip arthroplasty., Methods: From January 2018 to December 2019, 83 patients underwent primary total hip arthroplasty, including 28 males and 55 females, aged 42 to 81 (70.4±7.9) years. There were 63 cases of femoral neck fracture and 20 cases of avascular necrosis of femoral head. All patients used liquid crystal digital goniometer to control the anteversion of acetabular cup prosthesis during operation, and CT scanning was used to measure the anteversion of acetabular cup after operation. The two methods were compared to understand the accuracy of using liquid crystal digital goniometer., Results: Postoperative CT measurement showed that the acetabular anteversion of all patients was in the safe area advocated by Lewinnek. The anteversion angle of acetabular cup measured by liquid crystal digital goniometer was 14.20(12.80 to 15.40)°, and the anteversion angle of acetabular cup measured by postoperative CT scan was 14.20 (13.40 to 15.50)°. There was no significant difference between the two ( Z =-1.725, P =0.085)., Conclusion: It is an accurate and reliable method to control the anteversion of acetabular cup with liquid crystal digital display angle instrument, which has a good auxiliary reference value.
- Published
- 2021
- Full Text
- View/download PDF
24. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
- Author
-
Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, and Liu D
- Subjects
- Aged, Female, History, 21st Century, Humans, Male, Middle Aged, Hematologic Neoplasms drug therapy, Hematologic Neoplasms therapy
- Abstract
Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, "off-the-shelf" universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeting. Major developments and updates for the therapy of hematological malignancies were delineated at the recent Winter Symposium and New York Oncology Forum from the Chinese American Hematologist and Oncologist Network (CAHON.org). This study summarized the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.
- Published
- 2021
- Full Text
- View/download PDF
25. Proprioceptive training on the recovery of total knee arthroplasty patients: A meta-analysis protocol of randomized controlled trial.
- Author
-
Wu JQ, Bao HW, Mao LB, Liu LF, Li YM, Hou JZ, Wu CH, Zhou YJ, Wang Z, Cheng YX, and Wu J
- Subjects
- Humans, Meta-Analysis as Topic, Systematic Reviews as Topic, Osteoarthritis, Knee surgery, Proprioception physiology, Rehabilitation education, Rehabilitation methods, Rehabilitation trends
- Abstract
Background: Total knee arthroplasty is a common surgery for end-stage of knee osteoarthritis. Proprioceptive training has become an important part in athletes training programmes in different sports. However, the effects of proprioceptive training on the recovery of total knee arthroplasty were unknown. This meta-analysis, with its comprehensive and rigorous methodology, will provide better insight into this problem., Methods and Analysis: Electronic databases including PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure (CNKI) database, Wanfang Database and Chinese Biomedical Literature Database (CBM) were searched from its inception to October 21, 2020. We only included proprioceptive training vs placebo in patients after total knee arthroplasty and pooled results were summarized by STATA 12.0 software. Two researchers independently selected the study and assessed the quality of the included studies. The heterogeneity was measured by I2 tests (I2 < 50 indicates little heterogeneity, I2 ≥ 50 indicates high heterogeneity). Publication bias was ruled out by funnel plot and statistically assessed by Beggs test (P > .05 as no publication bias)., Results: Results will be published in relevant peer-reviewed journals., Conclusion: Our study aims to systematically present the clinical effects of proprioceptive training after total knee arthroplasty patients, which will be provide clinical guidance for total knee arthroplasty patients., Competing Interests: The authors have no conflicts of interests to disclose., (Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
26. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
- Author
-
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, and Panayiotidis P
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Mutation, Remission Induction, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Cytarabine administration & dosage, Leukemia, Myeloid, Acute drug therapy, Sulfonamides administration & dosage
- Abstract
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in this international phase 3 randomized double-blind placebo-controlled trial. Patients (N = 211) were randomized 2:1 to venetoclax (n = 143) or placebo (n = 68) in 28-day cycles, plus low-dose cytarabine (LDAC) on days 1 to 10. Primary end point was overall survival (OS); secondary end points included response rate, transfusion independence, and event-free survival. Median age was 76 years (range, 36-93 years), 38% had secondary AML, and 20% had received prior hypomethylating agent treatment. Planned primary analysis showed a 25% reduction in risk of death with venetoclax plus LDAC vs LDAC alone (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.52-1.07; P = .11), although not statistically significant; median OS was 7.2 vs 4.1 months, respectively. Unplanned analysis with additional 6-month follow-up demonstrated median OS of 8.4 months for the venetoclax arm (HR, 0.70; 95% CI, 0.50-0.98; P = .04). Complete remission (CR) plus CR with incomplete blood count recovery rates were 48% and 13% for venetoclax plus LDAC and LDAC alone, respectively. Key grade ≥3 adverse events (venetoclax vs LDAC alone) were febrile neutropenia (32% vs 29%), neutropenia (47% vs 16%), and thrombocytopenia (45% vs 37%). Venetoclax plus LDAC demonstrates clinically meaningful improvement in remission rate and OS vs LDAC alone, with a manageable safety profile. Results confirm venetoclax plus LDAC as an important frontline treatment for AML patients unfit for intensive chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03069352., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
27. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
- Author
-
Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, and Roboz GJ
- Subjects
- Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Bridged Bicyclo Compounds, Heterocyclic pharmacokinetics, Cytarabine administration & dosage, Cytarabine adverse effects, Cytarabine pharmacokinetics, Female, Humans, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Male, Middle Aged, Mutation, Sulfonamides administration & dosage, Sulfonamides adverse effects, Sulfonamides pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Myeloid, Acute drug therapy
- Abstract
Purpose: Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML., Patients and Methods: Adults 60 years or older with previously untreated AML ineligible for intensive chemotherapy were enrolled. Prior treatment of myelodysplastic syndrome, including hypomethylating agents (HMA), was permitted. Eighty-two patients were treated at the recommended phase II dose: venetoclax 600 mg per day orally in 28-day cycles, with LDAC (20 mg/m
2 per day) administered subcutaneously on days 1 to 10. Key end points were tolerability, safety, response rates, duration of response (DOR), and overall survival (OS)., Results: Median age was 74 years (range, 63 to 90 years), 49% had secondary AML, 29% had prior HMA treatment, and 32% had poor-risk cytogenetic features. Common grade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%). Early (30-day) mortality was 6%. Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count recovery (median time to first response, 1.4 months). The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR was 8.1 months (95% CI, 5.3 to 14.9 months). Among patients without prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months)., Conclusion: Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy. High remission rate and low early mortality combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for older adults not suitable for intensive chemotherapy.- Published
- 2019
- Full Text
- View/download PDF
28. Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy.
- Author
-
Hou JZ, Xi ZQ, Niu J, Li W, Wang X, Liang C, Sun H, Fang D, and Xie SQ
- Subjects
- Adult, Aminopyridines therapeutic use, Animals, Antineoplastic Agents therapeutic use, Apoptosis drug effects, Cell Line, Tumor, Cell Proliferation drug effects, ErbB Receptors metabolism, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Liver Neoplasms pathology, Male, Mice, Mice, Inbred BALB C, Phosphatidylinositol 3-Kinases metabolism, Xenograft Model Antitumor Assays, Aminopyridines pharmacology, Antineoplastic Agents pharmacology, Autophagy drug effects, Heterocyclic Compounds, 3-Ring pharmacology, Liver Neoplasms drug therapy, Phosphoinositide-3 Kinase Inhibitors
- Abstract
Liver cancer is among the most common types of cancer worldwide. The aim of the present study was to investigate whether the phosphatidylinositol‑3‑phosphate 5‑kinase (PIKfyve) inhibitor, YM201636, exerts anti‑proliferative effects on liver cancer. The methods used in the present study included MTT assay, flow cytometry, western blot analysis and an allograft mouse model of liver cancer. The results revealed that YM201636 inhibited the proliferation of HepG2 and Huh‑7 cells in a dose‑dependent manner. HepG2 and Huh‑7 cells exhibited strong monodansylcadaverine staining following treatment with YM201636. Accordingly, YM201636 treatment increased the expression of the autophagosome‑associated marker protein microtubule‑associated 1A/1B light chain 3‑II in HepG2 and Huh‑7 cells. The autophagy inhibitor 3‑methyladenine attenuated the inhibitory effects of YM201636 on liver cancer cell proliferation. Further in vivo analysis revealed that YM201636 (2 mg/kg) inhibited tumor growth without notable systemic toxicity. Mechanistic experiments demonstrated that YM201636 induced‑autophagy is dependent upon epidermal growth factor receptor (EGFR) overexpression in HepG2 and Huh‑7 cells. Collectively, these results suggested that the PIKfyve inhibitor YM201636 may inhibit tumor growth by promoting EGFR expression. This indicates that PIKfyve may be a potential therapeutic target for the treatment of liver cancer.
- Published
- 2019
- Full Text
- View/download PDF
29. Direct anterior versus lateral approaches for clinical outcomes after total hip arthroplasty: a meta-analysis.
- Author
-
Wang Z, Bao HW, and Hou JZ
- Subjects
- Arthroplasty, Replacement, Hip adverse effects, Humans, Length of Stay trends, Operative Time, Pain, Postoperative epidemiology, Treatment Outcome, Arthroplasty, Replacement, Hip methods, Arthroplasty, Replacement, Hip trends, Randomized Controlled Trials as Topic methods
- Abstract
Objective: To compare the outcomes of the direct anterior approach (DAA) with the lateral approach (LA) for total hip arthroplasty (THA) patients., Methods: Three English databases, PubMed, Embase, and the Cochrane Library, were searched for randomized controlled trials (RCTs) comparing the DAA with LA for THA. Information on the country, sample size, intervention, outcomes, and follow-up were extracted. Meta-analysis was performed using Stata 12.0., Results: Five RCTs totaling 475 patients (DAA = 236, LA = 239) were included in this meta-analysis. Compared with the LA, the DAA was associated with a reduction in the VAS at 6 weeks (weighted mean difference (WMD) = - 0.41, 95% confidence interval (CI) - 0.63 to - 0.19, P = 0.000) and total blood loss for THA patients (WMD = - 45.73, 95% CI - 84.72 to - 6.02, P = 0.024). Moreover, the DAA was associated with an increase in walking velocity (WMD = 5.01, 95% CI 2.32 to 7.70, P = 0.000), stride length (WMD = 3.12, 95% CI 2.42 to 3.82, P = 0.000), and step length (WMD = 4.09, 95% CI 1.03 to 7.14, P = 0.009) compared with the LA group. There was no significant difference between groups in the Harris hip score, operation time, transfusion rate, length of hospital stay, and the occurrence of complications., Conclusion: Current evidence demonstrated a trend showing that the DAA had a better effect on pain relief and blood-saving effects for THA patients. However, considering the number and sample size of the included trials, more large-scale RCTs with high quality are needed to confirm our conclusion.
- Published
- 2019
- Full Text
- View/download PDF
30. Location matters in early stage nodal diffuse large B-cell lymphoma.
- Author
-
Lontos K, Tsagianni A, Yuan JM, Normolle DP, Boyiadzis M, Hou JZ, Swerdlow SH, and Dorritie KA
- Subjects
- Adult, Aged, Chemoradiotherapy methods, Female, Humans, Kaplan-Meier Estimate, Lymph Node Excision, Lymph Nodes surgery, Lymphadenopathy mortality, Lymphadenopathy therapy, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse therapy, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, SEER Program statistics & numerical data, Young Adult, Lymph Nodes pathology, Lymphadenopathy pathology, Lymphoma, Large B-Cell, Diffuse mortality
- Published
- 2019
- Full Text
- View/download PDF
31. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
- Author
-
Li W, Hou JZ, Niu J, Xi ZQ, Ma C, Sun H, Wang CJ, Fang D, Li Q, and Xie SQ
- Subjects
- Active Transport, Cell Nucleus drug effects, Active Transport, Cell Nucleus genetics, Cell Nucleus drug effects, ErbB Receptors antagonists & inhibitors, Gefitinib pharmacology, Humans, MAP Kinase Signaling System drug effects, MAP Kinase Signaling System genetics, MCF-7 Cells, Neoplasm Metastasis, Phosphatidylinositol 3-Kinases metabolism, Breast Neoplasms pathology, Cell Nucleus metabolism, ErbB Receptors metabolism, Gene Knockdown Techniques, Proto-Oncogene Proteins c-akt deficiency, Proto-Oncogene Proteins c-akt genetics, beta Catenin metabolism
- Abstract
Background: Knockdown of Akt1 promotes Epithelial-to-Mesenchymal Transition in breast cancer cells. However, the mechanisms are not completely understood., Methods: Western blotting, immunofluorescence, luciferase assay, real time PCR, ELISA and Matrigel invasion assay were used to investigate how Akt1 inhibition promotes breast cancer cell invasion in vitro. Mouse model of lung metastasis was used to measure in vivo efficacy of Akt inhibitor MK2206 and its combination with Gefitinib., Results: Knockdown of Akt1 stimulated β-catenin nuclear accumulation, resulting in breast cancer cell invasion. β-catenin nuclear accumulation induced by Akt1 inhibition depended on the prolonged activation of EGFR signaling pathway in breast cancer cells. Mechanistic experiments documented that knockdown of Akt1 inactivates PIKfyve via dephosphorylating of PIKfyve at Ser
318 site, resulting in a decreased degradation of EGFR signaling pathway. Inhibition of Akt1 using MK2206 could induce an increase in the expression of EGFR and β-catenin in breast cancer cells. In addition, MK2206 at a low dosage enhance breast cancer metastasis in a mouse model of lung metastasis, while an inhibitor of EGFR tyrosine kinase Gefitinib could potentially suppress breast cancer metastasis induced by Akt1 inhibition., Conclusion: EGFR-mediated β-catenin nuclear accumulation is critical for Akt1 inhibition-induced breast cancer metastasis.- Published
- 2018
- Full Text
- View/download PDF
32. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
- Author
-
Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, and Johnson DE
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Dasatinib administration & dosage, Dasatinib adverse effects, Dasatinib pharmacokinetics, Drug Administration Schedule, Headache chemically induced, Humans, Leukemia, Myeloid metabolism, Leukemia, Myeloid pathology, Long QT Syndrome chemically induced, Middle Aged, Treatment Outcome, Tretinoin administration & dosage, Tretinoin adverse effects, Tretinoin pharmacokinetics, src-Family Kinases antagonists & inhibitors, src-Family Kinases metabolism, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid drug therapy
- Abstract
Src family kinases (SFKs) are hyperactivated in acute myeloid leukemia (AML). SFKs impede the retinoic acid receptor, and SFK inhibitors enhance all-trans retinoic acid (ATRA)-mediated cellular differentiation in AML cell lines and primary blasts. To translate these findings into the clinic, we undertook a phase-I dose-escalation study of the combination of the SFK inhibitor dasatinib and ATRA in patients with high-risk myeloid neoplasms. Nine subjects were enrolled: six received 70 mg dasatinib plus 45 mg/m
2 ATRA daily, and three received 100 mg dasatinib plus 45 mg/m2 ATRA daily for 28 days. Headache and QTc prolongations were the only two grade 3 adverse events observed. No significant clinical responses were observed. We conclude that the combination of 70 mg dasatinib and 45 mg/m2 ATRA daily is safe with acceptable toxicity. Our results provide the safety profile for further investigations into the clinical efficacy of this combination therapy in myeloid malignancies.- Published
- 2018
- Full Text
- View/download PDF
33. A systematic review and meta-analysis of direct anterior approach versus posterior approach in total hip arthroplasty.
- Author
-
Wang Z, Hou JZ, Wu CH, Zhou YJ, Gu XM, Wang HH, Feng W, Cheng YX, Sheng X, and Bao HW
- Subjects
- Aged, Female, Humans, Length of Stay, Middle Aged, Operative Time, Postoperative Complications, Postoperative Period, Treatment Outcome, Arthroplasty, Replacement, Hip methods
- Abstract
Background: This meta-analysis aimed to evaluate the postoperative clinical outcomes and safety of the direct anterior approach (DAA) versus posterior approach (PA) in total hip arthroplasty (THA)., Methods: We searched PubMed, Embase, Web of Science, the Cochrane Library, and Google databases from inception to June 2018 to select studies that compared the DAA and PA for THA. Only randomized controlled trials (RCTs) were included. Outcomes included Harris hip score at 2 weeks, 6 weeks, 12 weeks, and 1 year; VAS at 24 h, 48 h, and 72 h; incision length, operation time, postoperative blood loss, length of hospital stay, and complications (intraoperative fracture, postoperative dislocation, heterotopic ossification (HO), and groin pain)., Results: Nine RCTs totaling 754 THAs (DAA group = 377, PA group = 377) met the criteria to be included in this meta-analysis. The present meta-analysis indicated that, compared with PA group, DAA group was associated with an increase of the Harris hip score at the 2-week and 4-week time points. No significant difference was found between DAA and PA groups of the Harris hip scores at 12 weeks, 1 year length of hospital stay (p > 0.05). DAA group was associated with a reduction of the VAS at 24 h, 48 h, and 72 h with statistical significance (p < 0.05). What is more, DAA was associated with a reduction of the incision length and postoperative blood loss (p < 0.05). There was no significant difference between the operation time and complications (intraoperative fracture, postoperative dislocation, HO, and groin pain)., Conclusion: In THA patients, compared with PA, DAA was associated with an early functional recovery and less pain scores. What is more, DAA was associated with shorter incision length and blood loss.
- Published
- 2018
- Full Text
- View/download PDF
34. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
- Author
-
Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, and Salles G
- Subjects
- Adenine analogs & derivatives, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor immunology, Female, Humans, Lymphoma, Follicular immunology, Male, Middle Aged, Piperidines, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Pyrazoles adverse effects, Pyrimidines adverse effects, Recurrence, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, Treatment Outcome, Lymphoma, Follicular drug therapy, Pyrazoles therapeutic use, Pyrimidines therapeutic use
- Abstract
Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee-assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle 3) and cytokines/chemokines (baseline/cycle 2) were performed for available samples. Results Between March 2013 and May 2016, 110 patients with a median of three prior lines of therapy were enrolled. At median follow-up of 27.7 months, ORR was 20.9% (95% CI, 13.7% to 29.7%, which did not meet the 18% lower-bound threshold for the primary end point). Twelve patients achieved a complete response (11%; 95% CI, 5.8% to 18.3%). Median duration of response was 19.4 months (range, 1 to ≥ 33 months), with a median progression-free survival of 4.6 months and a 30-month overall survival of 61% (95% CI, 0.51% to 0.70%). Lymphoma symptoms resolved in 67%. Seven of 32 patients who experienced initial radiologic progression responded upon continuing therapy (pseudoprogression). The most common adverse events were diarrhea, fatigue, cough, and muscle spasms; 48.2% of patients reported serious adverse events. In patients who experienced a response, regulatory T cells were downregulated at C3D1 ( P = .02), and Th1-promoting (antitumor) cytokines interferon-γ and interleukin-12 increased ( P ≤ .035). Conclusion With an ORR of 20.9%, ibrutinib failed to meet its primary efficacy end point in chemoimmunotherapy in patients with relapsed/refractory FL, although responses were durable and associated with a reduction in regulatory T cells and increases in proinflammatory cytokines.
- Published
- 2018
- Full Text
- View/download PDF
35. Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery.
- Author
-
Wu ZF, Wang Y, Yang P, Hou JZ, Zhang JY, Hu Y, and Zeng ZC
- Abstract
Locally advanced hepatocellular carcinoma (HCC) treated by radiotherapy (RT) may be suited for further treatment with surgery. As a critical mediator of the post-RT immune response, Toll-like receptor 4 (TLR4) and its associated proteins may serve as prognostic factors for patients with HCC treated by post-RT surgery. In the present study, a total of 20 patients with HCC treated by post-RT surgery were enrolled. Resected tumor and peritumoral liver tissues were used to construct tissue microarrays that were assessed with immunohistochemical staining for the expression levels of TLR4, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and vascular endothelial growth factor receptor 2 (VEGFR2). The overall (OS) and disease-free (DFS) survival outcomes for each patient were assessed, and the severity of radiation-induced liver diseases (RILDs) was detected. The patients with low TLR4 or TRAIL expression exhibited significantly better OS times than those with high TLR4 (P=0.003) or TRAIL (P=0.007) expression, whereas the median DFS times for patients with low VEGFR2 or TRAIL were significantly longer than those with high VEGFR2 (P=0.003) or TRAIL (P=0.008) expression. No significant differences in OS or DFS times were identified according to the expression of TLR4, VEGFR2 or TRAIL in peritumoral liver tissue, although more severe RILDs were identified in patients with the high expression of these factors in the peritumoral liver tissue post-RT (P<0.05). Therefore, the expression levels of TLR4 and its associated proteins in HCC tumors may be suitable as prognostic factors for patients with HCC treated by post-RT surgery. The inhibition of TLR4, VEGFR2 and TRAIL expression in HCC and non-tumor liver tissue may lessen the severity of RILDs and improve survival outcomes in the future.
- Published
- 2018
- Full Text
- View/download PDF
36. Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.
- Author
-
Lim MJ, Agha A, Im A, Raptis A, Hou JZ, Boyiadzis M, Sehgal AR, Redner RL, Dorritie K, Marks SS, Agha ME, and Lim SH
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Female, Humans, Male, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Induction Chemotherapy, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality
- Published
- 2018
- Full Text
- View/download PDF
37. Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen.
- Author
-
Posluszny DM, Bovbjerg DH, Agha ME, Hou JZ, Raptis A, Boyiadzis MM, Dunbar-Jacob J, Schulz R, and Dew MA
- Subjects
- Humans, Patient Education as Topic, Transplantation, Homologous, Adaptation, Psychological, Caregivers psychology, Hematopoietic Stem Cell Transplantation psychology, Treatment Adherence and Compliance psychology
- Published
- 2018
- Full Text
- View/download PDF
38. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation.
- Author
-
Zhao Y, Ge CC, Wang J, Wu XX, Li XM, Li W, Wang SS, Liu T, Hou JZ, Sun H, Fang D, and Xie SQ
- Subjects
- Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Movement drug effects, Cell Nucleolus drug effects, Cell Proliferation drug effects, Female, Humans, MAP Kinase Kinase Kinases antagonists & inhibitors, MAP Kinase Kinase Kinases genetics, MAP Kinase Signaling System drug effects, MCF-7 Cells, Protein Kinase Inhibitors administration & dosage, Breast Neoplasms drug therapy, ErbB Receptors genetics, Flavonoids administration & dosage, beta Catenin genetics
- Abstract
Abnormal activation of the RAF/MEK/ERK signaling pathway has been observed in breast cancer. Thus, a number of MEK inhibitors have been designed as one treatment option for breast cancer. Although some studies have found that these MEK inhibitors inhibit the growth of a variety of human cancer cells, some trials have shown that the use of MEK inhibitors as a treatment for breast cancer does not adequately improve survival for unknown reasons. In the present study, MEK inhibitor PD98059 was used to evaluate its anticancer effects on human breast cancer MCF-7 and MDA-MB-231 cells and to explore the possible mechanism of action. Our results revealed that MEK inhibitor PD98059 exhibited antiproliferative effects in a dose- and time-dependent manner in MCF-7 and MDA-MB-231 breast cancer cells. Conversely, incubation of MCF-7 and MDA-MB-231 cells with PD98059 promoted their migration. Further investigation disclosed that the enhanced ability of migration promoted by PD98059 was dependent on β-catenin nuclear translocation in the MCF-7 and MDA-MB‑231 cells. Subsequent experiments documented that activation of EGFR signaling induced by PD98059 increased the amount of β-catenin in the nucleus. Taken together, our findings may elucidate a possible mechanism explaining the ineffectiveness of MEK inhibitors in breast cancer treatment and improve our understanding of the role of MEK in cancer.
- Published
- 2017
- Full Text
- View/download PDF
39. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
- Author
-
Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, and Whiteside TL
- Subjects
- Aged, Aged, 80 and over, Cell Transplantation adverse effects, Cell Transplantation methods, Cytokines blood, Female, Humans, Immunotherapy, Adoptive adverse effects, Interleukin-2 pharmacology, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Treatment Outcome, Immunotherapy, Adoptive methods, Killer Cells, Natural transplantation, Leukemia, Myeloid, Acute therapy
- Abstract
Background Aims: Activated NK cells (aNK) generated by expansion of a human interleukin-2-dependent NK cell line (NK-92) were shown to mediate strong anti-leukemia activity. This phase 1 study evaluated feasibility, safety, and activity of aNK cells adoptively transferred to patients with refractory/relapsed acute myeloid leukemia (AML). In addition, effects of these aNK cells on the patient's immune system were evaluated., Methods: Two cell-dose levels (1 × 10
9 cells/m2 and 3 × 109 cells/m2 ) were used. One treatment course consisted of two infusions of the same cell dose, each cell infusion delivered 24 h apart. The aNK cells were administered in the outpatient setting., Results: Seven patients with refractory/relapsed AML were treated with a total of 20 aNK cell infusions. None of the 7 patients experienced dose-limiting toxicities during the aNK cell administration or during 21 days of the post-infusion observation period. No grade 3-4 toxicities (probable or definite) related to aNK cell infusions occurred. Activity was transient in 3 of 7 patients. No significant changes in the patient's lymphocyte counts, subsets frequency, phenotype or activity were observed post-infusion. Cell dose-dependent effects in the plasma levels of several cytokines were observed., Discussion: The trial demonstrated the safety and feasibility of adoptive cell therapy with "off-the-shelf" aNK cells in patients with refractory/relapsed AML. These data provide the foundation for future combination immunotherapy trials and for the optimization of aNK cell based therapies in patients with AML., (Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
40. Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.
- Author
-
Lontos K, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Gooding WE, Humar A, and Boyiadzis M
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Survival Analysis, Treatment Outcome, Leukemia, Myeloid, Acute etiology, Organ Transplantation, Postoperative Complications diagnosis, Postoperative Complications mortality, Postoperative Complications therapy
- Abstract
Organ transplant recipients are at an increased risk for subsequent cancer including acute myeloid leukemia (AML). Treatment of AML following solid transplantation represents a clinical challenge as most patients have significant comorbidities at the time of AML diagnosis. In this study, we evaluated the treatment and outcomes of patients who developed AML following solid organ transplantation at our institution and reviewed the literature on outcomes for these patients. The study cohort consisted of 14 patients (median age 66 years, range 52-77 years) with newly diagnosed AML following solid organ transplantation. The median interval time between solid organ transplantation and AML diagnosis was 72 months (range 15-368 months). Seven patients received standard induction chemotherapy, four patients received intermediate type therapy, and the remaining three patients were deemed not fit for therapy and received palliative and supportive care. Six of the 11 treated patients (55%) achieved complete remission (CR). The median overall survival (OS) for all patients was 6 months. The median OS for the patients who achieved complete remission after therapy was 17 months and 2 months for the remaining patients. Despite initial CR, relapse rates are still high, suggesting that alternative strategies for post-remission therapies are warranted., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
41. Leukapheresis in patients newly diagnosed with acute myeloid leukemia.
- Author
-
Villgran V, Agha M, Raptis A, Hou JZ, Farah R, Lim SH, Redner RL, Im A, Sehgal A, Dorritie KA, Kiss JE, Normolle D, and Boyiadzis M
- Subjects
- Adult, Aged, Aged, 80 and over, Blast Crisis blood, Blast Crisis diagnosis, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute diagnosis, Male, Middle Aged, Survival Rate, Blast Crisis mortality, Blast Crisis therapy, Leukapheresis, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy
- Abstract
Hyperleukocytosis is present in 5 to 20 percent of patients with newly diagnosed acute myeloid leukemia (AML). The management of hyperleukocytosis, when symptoms of leukostasis occur, includes intensive supportive care and interventions for rapid cytoreduction. Leukapheresis is a rapid and effective means of cytoreduction and has been used in AML patients. In the current study, we evaluated the outcomes of 68 newly diagnosed AML patients that underwent leukapheresis and the effects of leukapheresis on various laboratory parameters. A total of 127 leukapheresis cycles were performed. The median number of leukapheresis cycles was 2 (range, 1-8). The overall survival for all patients was 4.2 months (95% CI 1.2-9.7 months). The median overall survival for patients who achieved complete remission after induction chemotherapy was significantly higher (19.1 months [95% CI 12.1-41.8 months]) than patients that did not achieve complete remission (0.46 months [95% CI 0.33-0.99 months]). Stepwise logistic regression demonstrated that elevated number of peripheral blasts, low platelet count and elevated bilirubin at AML diagnosis were predictive of death within a week. Leukapheresis was effective in reducing the peripheral blood leukocytes and leukemia blasts and was a safe procedure with regard to organ function, coagulation parameters, red blood cells and platelet count. The high initial response rates in newly diagnosed AML patients fit to receive intensive chemotherapy suggest that leukapheresis could be beneficial in reducing the complications associated with hyperleukocytosis until systemic intensive chemotherapy commences., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
42. [Application of microscopic spectroscopy in quality control of Niuhuang Qingxin pills].
- Author
-
Nie LX, Zhang Y, Zhang NP, Hu XR, Kang S, Hou JZ, Dai Z, and Ma SC
- Subjects
- Drug Contamination, Medicine, Chinese Traditional, Drugs, Chinese Herbal standards, Quality Control, Spectrum Analysis
- Abstract
Application of microscopic spectroscopy in quality control of Niuhuang Qingxin pills was discussed. First, microscopic characteristics specified by the statutory standard of Niuhuang Qingxin pills were summarized. Then new identification method was established for Dioscoreae Rhizoma, Saigae Tataricae Cornu, Cinnamomi Cortex and Saposhnikoviae Radix. Finally, microscopic spectroscopy was used for test of Dioscoreae Rhizoma's adulterant Dioscoreae Fordii Rhizoma.It was the first time for this technology being applied in adulteration test of Chinese patent medicine.The results showed that Saigae Tataricae Cornu was not detected in 2 batches of Niuhuang Qingxin pills from 1 manufacturer while Dioscoreae Fordii Rhizoma was detected in 3 batches of samples from 2 manufacturers. The proposed methods were accurate, simple, rapid, objective and economic, which offered a more comprehensive approach for quality control of Niuhuang Qingxin pills. It was indicated that conventional technology such as microscopic spectroscopy could play an important role in identification of traditional Chinese medicine whose index ingredient was deficient or tiny., Competing Interests: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose., (Copyright© by the Chinese Pharmaceutical Association.)
- Published
- 2016
- Full Text
- View/download PDF
43. ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.
- Author
-
Hartsock B, Lim MJ, Roth CG, Raptis N, Weber D, Sehgal A, Boyiadzis M, Raptis A, Hou JZ, Im A, Dorritie K, Marks S, Agha M, and Lim SH
- Subjects
- Adult, Aged, Female, Hematologic Tests, Humans, Induction Chemotherapy, Inflammatory Bowel Diseases, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Retrospective Studies, Risk Factors, Time Factors, Young Adult, Intensive Care Units statistics & numerical data, Leukemia, Myeloid, Acute diagnosis
- Abstract
We carried out a retrospective study on newly diagnosed AML patients to identify the risk factors associated with intensive care unit (ICU) intervention. One hundred and twenty consecutive AML patients were included. The median cycle of induction therapy (IT) was 2 (range 1-4). Ten patients (8%) needed ICU intervention during IT. The median time from first IT to ICU transfer was 16days (range 2-88days). Three patients required vasopressor/s, three mechanical ventilation, and four both. The cumulative probability for ICU intervention rose progressively with increasing cycles of IT received, from 2.5% during first induction to 27.5% at fourth induction. Age, sex, presentation white cell counts and coagulation profiles, cytogenetics, pre-chemotherapy ventricular ejection fractions, and prior chemoradiation were not risk factors. Univariate analysis identified a history of inflammatory bowel disease (IBD) (p=0.004) (RR=5.7; p=0.03) and positive blood cultures (BC) (p=0.03) (RR=3; p=0.06) as significant risks. Multivariate analysis found a history of IBD as the only significant factor (p=0.03), while positive BC (p=0.1) trending towards significance. AML patients with a history of IBD and positive BC are at increased risks for ICU intervention during IT., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
44. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT.
- Author
-
Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, and Mo HF
- Subjects
- Adult, Aged, Feasibility Studies, Female, Humans, Imaging, Three-Dimensional, Liver Neoplasms mortality, Male, Middle Aged, Radiotherapy Dosage, Retrospective Studies, Treatment Outcome, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy, Neoplastic Cells, Circulating, Portal Vein pathology, Radiotherapy, Conformal methods, Radiotherapy, Intensity-Modulated methods, Vena Cava, Inferior pathology
- Abstract
Objective: To compare the efficacies of conventional three-dimensional conformal radiotherapy and image-guided hypofractionated intensity-modulated radiotherapy treatments in advanced hepatocellular carcinoma patients with portal vein and/or inferior vena cava tumor thrombi., Methods: A total of 118 hepatocellular carcinoma patients with portal vein and/or inferior vena cava tumor thrombi who received external beam radiation therapy focused on tumor thrombi and intrahepatic tumors were retrospectively reviewed. During the three-dimensional conformal radiotherapy treatments, a median total dose of 54 Gy with a conventional fraction (1.8-2.0 Gy/fx) was delivered. During the image-guided hypofractionated intensity-modulated radiotherapy treatments, a median total dose of 60 Gy with fractions of 2.5-4.0 Gy/fx was delivered., Results: The median follow-up time was 11.8 months (range, 1.7-43.7 months). Higher radiation doses were delivered by image-guided hypofractionated intensity-modulated radiotherapy than by three-dimensional conformal radiotherapy (average dose 57.86 ± 7.03 versus 50.88 ± 6.60 Gy, P ≤ 0.001; average biological effective dose 72.35 ± 9.62 versus 61.45 ± 6.64 Gy, P < 0.001). A longer median survival was found with image-guided hypofractionated intensity-modulated radiotherapy than with three-dimensional conformal radiotherapy (15.47 versus 10.46 months, P = 0.005). Multivariate analysis showed that image-guided hypofractionated intensity-modulated radiotherapy is a significant prognostic factor for overall survival. Toxicity was mild for both image-guided hypofractionated intensity-modulated radiotherapy and three-dimensional conformal radiotherapy., Conclusions: High dose radiotherapy delivered by image-guided hypofractionated intensity-modulated radiotherapy appears to be an effective treatment that provides a survival benefit without increasing severe toxicity in hepatocellular carcinoma patients with portal vein and/or inferior vena cava tumor thrombi., (© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
45. Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
- Author
-
Agha A, Sehgal A, Lim MJ, Weber D, Hou JZ, Farah R, Raptis A, Im A, Dorritie K, Marks S, Agha M, and Lim SH
- Subjects
- Adult, Aged, Clostridioides difficile drug effects, Clostridium Infections microbiology, Female, Graft vs Host Disease mortality, Hematologic Neoplasms mortality, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Transplantation, Homologous, Treatment Outcome, Young Adult, Antibiotic Prophylaxis, Clostridioides difficile isolation & purification, Clostridium Infections prevention & control, Graft vs Host Disease prevention & control, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Clostridium difficile infections (CDI) remain the leading cause of infectious diarrhea among hospitalized patients in this country. Patients with hematologic malignancies, especially those who undergo hematopoietic progenitor cell transplants are particularly at risk for developing CDI. One hundred and forty seven consecutive allogeneic hematopoietic progenitor cell transplants were analyzed for peri-transplant Clostridium difficile infections (PT-CDI). Sixteen patients (11%) developed PT-CDI (Median time = 7 days after transplant). The probability for developing PT-CDI during the peri-transplant period was 12.3%. History of CDI was strongly associated with the development of PT-CDI (P = 0.008) (OR = 5.48) (P = 0.017). These patients also developed PT-CDI much earlier than in those without a history (median 1 day vs. 8 days, P = 0.03). The probability for developing PT-CDI for those with a history was 39%. There was a trend toward significance (P = 0.065) between matched related donor grafts and the development of PT-CDI (OR = 0.245) (P = 0.08). Age, sex, diagnosis, transplant preparative regimens, Graft-versus-host disease (GVHD) prophylaxis, grade 3/4 acute GVHD, or use of antimicrobials within 8 weeks of transplant were not associated with PT-CDI. Non-CDI-related deaths occurred in one patient in the PT-CDI group and nine in the group without PT-CDI. In the remaining 139 patients, the length of hospital stay for those with PT-CDI was significantly longer than those without (mean 27 days vs. 22 days; P = 0.02)., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
46. [Characteristics and Risk Assessment of Heavy Metals in Core Sediments from Lakes of Tibet].
- Author
-
Guo BX, Liu YQ, Zhang F, Hou JZ, and Zhang HB
- Subjects
- Carbon analysis, Lakes chemistry, Risk Assessment, Soil chemistry, Tibet, Environmental Monitoring, Geologic Sediments analysis, Metals, Heavy analysis, Water Pollutants, Chemical analysis
- Abstract
To explore the source of heavy metals in lake sediments and their hazard to environment on Tibetan Plateau, China, heavy metal (Cu, Zn, Cd, Pb, Cr, Co, Ni and As) levels in surface sediments of 18 lakes were investigated. Inductively Coupled Plasma Mass Spectrometry (ICP-MS, X-7 series) was used to determine the contents of heavy metals and the concentrations of carbon and nitrogen in sediment samples were analyzed by element analyzer (Vario Max CN, Elementar, Germany). The average concentrations for Cu, Zn, Cd, Pb, Cr, Co, Ni and As were 24.61 mg x kg(-1), 70.14 mg x kg(-1), 0.26 mg x kg(-1), 25.43 mg x kg(-1), 74.12 mg x kg(-1), 7.93 mg x kg(-1), 33.85 mg x kg(-1), 77.69 mg x kg(-1). It was found that heavy-metal concentrations in Tibet sediments were higher than those in Antarctic, but lower than those in the regions affected by anthropogenic activities. The contents of Cu, Zn, Pb, Cr and Co in the samples were lower than the background values of Tibet. Correlation analysis and principal components analysis (PCA) were used to analyze the origins of heavy metals. The result showed that Cu, Zn, Cd, Pb, Co, Ni and As came from soil in drainage basin and atmospheric deposition. Cr was mainly affected by human activities. Assessment on ecological risk of heavy metals was carried out using Hakanson's method and cluster analysis (CA). Assessment on ecological risk indicated that Pumoyum Co, Longmo Co and Bangong Co were at low risks, Bieruoze Co was at high ecological risk level and the other lakes were at different risk levels.
- Published
- 2016
47. Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant.
- Author
-
Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks S, Im A, Dorritie K, Sehgal A, Agha M, and Lim SH
- Subjects
- Adult, Aged, Allografts, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Solitary Pulmonary Nodule mortality, Solitary Pulmonary Nodule pathology, Solitary Pulmonary Nodule therapy
- Abstract
Pulmonary nodules (PNs) develop frequently in patients with acute myeloid leukemia (AML). They are of infectious or inflammatory origin. They pose potential challenges to successful hematopoietic progenitor cell (HPC) transplant as they may be niches for infection reactivation or sites susceptible to subsequent infections. We retrospectively analyzed the outcome of 20 AML patients with multiple PNs who underwent allogeneic HPC transplants (12 related, 8 unrelated). There were 13 males and seven females (median age 52 yrs). Nine patients were in CR1, seven in CR2, and four with residual disease. The median times from appearance of PNs and from last positive CT scans to transplant were three and two months, respectively. The median time from pretransplant CT scans to transplant was one month. Multiple PNs were still reported in 5/20 of the pretransplant scans. The PNs in all five patients did not worsen after transplant. Four patients (one with positive pretransplant CT scan) died within the first 100 d after transplant, but none from primary pulmonary pathology. The median survival of this group of patients was 350 d. Our results, therefore, suggest that multiple PNs of uncertain etiology in patients with AML do not impact adversely on the outcome of allogeneic HPC transplant., (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
48. Flow Cytometric Evaluation of Double/Triple Hit Lymphoma.
- Author
-
Roth CG, Gillespie-Twardy A, Marks S, Agha M, Raptis A, Hou JZ, Farah R, Lin Y, Qian Y, Pantanowitz L, and Boyiadzis M
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD19 immunology, Antigens, CD20 immunology, Female, Gene Expression Regulation, Neoplastic immunology, Humans, Leukocyte Common Antigens immunology, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 immunology, Proto-Oncogene Proteins c-bcl-6 genetics, Proto-Oncogene Proteins c-bcl-6 immunology, Proto-Oncogene Proteins c-myc genetics, Proto-Oncogene Proteins c-myc immunology, Flow Cytometry, Immunophenotyping, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Translocation, Genetic genetics
- Abstract
"Double" or "triple" hit lymphomas (D/THL) with recurrent translocations involving MYC/8q24 and BCL2/18q21 and/or BCL6/3q27 are characterized by a poor prognosis, but their identification is hampered by the clinicopathologic overlap with other disease categories. Cases with circulating blastic-appearing cells may initially cause concern for lymphoblastic leukemia a diagnostic dilemma, which has not been well studied. There is only limited literature regarding the flow cytometric (FC) D/THL phenotype and its clinical correlates. The FC features of 20 D/THL (11 BCL2(+)/MYC(+), 5 BCL6(+)/MYC(+), 4 BCL2(+)/BCL6(+)/MYC(+)) were evaluated, compared to 20 B-lymphoblastic leukemias (B-LBL), and correlated with overall survival. Most (89%, 17/19) D/THL were CD10(+), 47% (9/19) lacked surface light chain, and a significant subset underexpressed CD45 (47%, 9/19), CD20 (42% 8/19), and/or CD19 (39%, 7/18), which did not vary by genetic subgroup. Compared to B-LBL, D/THL less frequently underexpressed CD45 (p = 0.0001) and CD20 (p = 0.0004). Lower levels of BCL2 expression were noted in the BCL6(+)/MYC(+) and BCL2(+)/BCL6(+)/MYC(+) subgroups versus BCL2(+)/MYC(+) cases (p = 0.0014). Of the flow cytometric parameters assessed, dim CD45 expression correlated with inferior survival (p = 0.01). Although there is some overlap with B-LBL, D/THL demonstrates a characteristic immunophenotype which may have prognostic significance and warrants further investigation.
- Published
- 2016
- Full Text
- View/download PDF
49. Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature.
- Author
-
Im A, Raptis A, Hou JZ, Tompkins C, Winfield M, Guay M, Boyiadzis M, and Agha M
- Subjects
- Graft vs Host Disease, Hematologic Neoplasms, Humans, Middle Aged, Recurrence, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning
- Abstract
Background/aims: Relapse is a leading cause of mortality after allogeneic hematopoietic cell transplantation (HCT). Hypomethylating agents (HMAs) have immunomodulatory properties, including augmenting tumor antigen presentation that may enhance the graft-versus-leukemia effect. Moreover, inhibitory effects on T-cell activation and cytokine production may lead to a lower incidence of graft-versus-host disease (GVHD). Our aim was to describe outcomes in patients treated with HMAs for relapse after HCT., Methods: Subjects were retrospectively identified as patients with relapse or loss of donor chimerism after HCT for myeloid malignancies treated with HMAs at the University of Pittsburgh., Results: Thirteen patients were identified, with a median age of 57 years and a median time to relapse of 98 days. Nine of 12 (75%) evaluable patients had a complete remission (CR). Grade I-IV acute GVHD involving the liver occurred in 6 patients. Cases of acute liver GVHD were diagnosed clinically based on the elevation of liver function tests. The median survival was 14.3 months from the time of relapse., Conclusion: HMAs for relapse after HCT can be effective in inducing a CR. This may be due to epigenetic changes and immunomodulatory effects that enhance the graft-versus-leukemia effect. There may be a risk of GVHD, and further exploration into pathophysiology and predisposing factors are warranted., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
50. Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.
- Author
-
Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, Lim S, Sehgal A, Dorritie KA, Redner RL, McLaughlin B, Shuai Y, Duggal S, and Boyiadzis M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cytogenetic Analysis, Etoposide administration & dosage, Female, Humans, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Mitoxantrone administration & dosage, Prognosis, Recurrence, Survival Analysis, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy
- Abstract
Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone-etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median overall survival for all patients was 7.4 months. The survival of patients who achieved CR and underwent allogeneic hematopoietic cell transplantation (allo-HCT) was higher than those who achieved CR and did not undergo allo-HCT (35.3 months vs. 16.8 months, p = 0.057). The median duration of relapse-free survival was 12.7 months in the patients achieving CR. Older age at the time of AML relapse was associated with worse overall survival. The all-cause 4-week mortality rate was 4%, and the all-cause 8-week mortality rate was 13%. The findings of this study underscore the need for newer therapies, especially those that will improve the ability for patients with relapsed AML to achieve CR and to allow them to receive additional therapies.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.